Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7534.098 | 1.0237 | 1.0510 | 0.9286 | |
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7534.098 | 0.9794 | 0.9556 | 0.9286 | |
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7534.098 | 0.9880 | 0.9742 | 0.9286 | |
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7534.098 | 0.7443 | 0.4552 | 0.9286 | |
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7534.098 | 0.4247 | -0.2048 | 0.9286 | |
| SUM225CWN | HER2amp | Basal A | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7534.098 | 0.3652 | -0.3240 | 0.9286 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7535.098 | 0.9762 | 0.9526 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7535.098 | 0.9207 | 0.8420 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7535.098 | 0.9937 | 0.9874 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7535.098 | 0.9471 | 0.8945 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7535.098 | 0.9991 | 0.9981 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7535.098 | 0.9581 | 0.9164 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7535.098 | 0.9594 | 0.9190 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7535.098 | 0.9219 | 0.8443 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7535.098 | 0.9876 | 0.9753 | 1.0037 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7537.098 | 0.9619 | 0.9593 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7537.098 | 0.9582 | 0.9553 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7537.098 | 0.9522 | 0.9488 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7537.098 | 0.9858 | 0.9849 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7537.098 | 0.9855 | 0.9846 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7537.098 | 0.9528 | 0.9494 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7537.098 | 0.8777 | 0.8666 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7537.098 | 0.7620 | 0.7319 | 1.8887 | |
| SUM229PE | TNBC | - | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7537.098 | 0.6062 | 0.5343 | 1.8887 | |
| SUM52PE | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7539.098 | 0.9754 | 0.9695 | 1.6240 |